Multiple Myeloma Coverage from Every Angle

Tarek H. Mouhieddine, MD, on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma With Bispecific Antibodies Treatment

Posted: Sunday, December 12, 2021

Tarek H. Mouhieddine, MD, of The Mount Sinai Hospital and The Icahn School of Medicine at Mount Sinai, discusses findings on the optimal treatment sequences for patients with multiple myeloma who relapse after treatment with bispecific antibodies and the research still needed.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.